메뉴 건너뛰기




Volumn 8, Issue 22, 2017, Pages 35508-35522

Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: A strategy to overcome TP53 mutated/ deleted clones

Author keywords

Chronic lymphocytic leukemia; MiR181; MiR338; PTEN; USP7

Indexed keywords

ANTINEOPLASTIC AGENT; CASEIN KINASE II; DEUBIQUITINASE; MICRORNA; MICRORNA 181B; MICRORNA 338 3P; P 5091; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; UNCLASSIFIED DRUG; USP7 PROTEIN; PTEN PROTEIN, HUMAN; UBIQUITIN CARBOXYL TERMINAL HYDROLASE 7; USP7 PROTEIN, HUMAN;

EID: 85021711548     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16348     Document Type: Article
Times cited : (61)

References (63)
  • 1
    • 84914688977 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia: a clinical review
    • Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014; 312: 2265-76. doi: 10.1001/ jama.2014.14553
    • (2014) JAMA , vol.312 , pp. 2265-2276
    • Nabhan, C.1    Rosen, S.T.2
  • 2
    • 84904411900 scopus 로고    scopus 로고
    • Evolving understanding of the CLL genome
    • Gruber M, Wu CJ. Evolving understanding of the CLL genome. Semin Hematol. 2014; 51: 177-87. doi: 10.1053/j. seminhematol.2014.05.004
    • (2014) Semin Hematol , vol.51 , pp. 177-187
    • Gruber, M.1    Wu, C.J.2
  • 4
    • 84887821409 scopus 로고    scopus 로고
    • Molecular bases of chronic lymphocytic leukemia in light of new treatments
    • Rossi D, Ciardullo C, Spina V, Gaidano G. Molecular bases of chronic lymphocytic leukemia in light of new treatments. Immunol Lett. 2013; 155: 51-5. doi: 10.1016/j. imlet.2013.09.010
    • (2013) Immunol Lett , vol.155 , pp. 51-55
    • Rossi, D.1    Ciardullo, C.2    Spina, V.3    Gaidano, G.4
  • 5
    • 84867154468 scopus 로고    scopus 로고
    • Molecular pathogenesis of chronic lymphocytic leukemia
    • Gaidano G, Foà R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012; 122: 3432-8. doi: 10.1172/JCI64101
    • (2012) J Clin Invest , vol.122 , pp. 3432-3438
    • Gaidano, G.1    Foà, R.2    Dalla-Favera, R.3
  • 8
    • 84937551978 scopus 로고    scopus 로고
    • Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53
    • Zent CS, Burack WR. Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program. 2014; 2014: 119-24. doi: 10.1182/asheducation-2014.1.119
    • (2014) Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program , vol.2014 , pp. 119-124
    • Zent, C.S.1    Burack, W.R.2
  • 9
    • 84955438788 scopus 로고    scopus 로고
    • Progress in Chronic Lymphocytic Leukemia with Targeted Therapy
    • Wilson WH. Progress in Chronic Lymphocytic Leukemia with Targeted Therapy. N Engl J Med. 2016; 374: 386-8. doi: 10.1056/NEJMe1515235
    • (2016) N Engl J Med , vol.374 , pp. 386-388
    • Wilson, W.H.1
  • 10
    • 84896689612 scopus 로고    scopus 로고
    • PI3-kinase inhibitors in chronic lymphocytic leukemia
    • Chang JE, Kahl BS. PI3-kinase inhibitors in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2014; 9: 33-43. doi: 10.1007/s11899-013-0189-7
    • (2014) Curr Hematol Malig Rep , vol.9 , pp. 33-43
    • Chang, J.E.1    Kahl, B.S.2
  • 11
    • 84944755146 scopus 로고    scopus 로고
    • Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies
    • Xia B, Qu F, Yuan T, Zhang Y. Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies. Oncol Lett. 2015; 10: 3339-44. doi: 10.3892/ ol.2015.3802
    • (2015) Oncol Lett , vol.10 , pp. 3339-3344
    • Xia, B.1    Qu, F.2    Yuan, T.3    Zhang, Y.4
  • 22
    • 80052468466 scopus 로고    scopus 로고
    • p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies
    • Wickremasinghe RG, Prentice AG, Steele AJ. p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies. Leukemia. 2011; 25: 1400-7. doi: 10.1038/leu.2011.103
    • (2011) Leukemia , vol.25 , pp. 1400-1407
    • Wickremasinghe, R.G.1    Prentice, A.G.2    Steele, A.J.3
  • 23
    • 0037393911 scopus 로고    scopus 로고
    • Disparate expression of the PTEN gene: a novel finding in B-cell chronic lymphocytic leukaemia (B-CLL)
    • Leupin N, Cenni B, Novak U, Hügli B, Graber HU, Tobler A, Fey MF. Disparate expression of the PTEN gene: a novel finding in B-cell chronic lymphocytic leukaemia (B-CLL). Br J Haematol. 2003; 121: 97-100
    • (2003) Br J Haematol , vol.121 , pp. 97-100
    • Leupin, N.1    Cenni, B.2    Novak, U.3    Hügli, B.4    Graber, H.U.5    Tobler, A.6    Fey, M.F.7
  • 24
    • 84877761870 scopus 로고    scopus 로고
    • Low expression level of phosphatase and tensin homolog deleted on chromosome ten predicts poor prognosis in chronic lymphocytic leukemia
    • Zou ZJ, Zhang R, Fan L, Wang L, Fang C, Zhang LN, Yang S, Li YY, Li JY, Xu W. Low expression level of phosphatase and tensin homolog deleted on chromosome ten predicts poor prognosis in chronic lymphocytic leukemia. Leuk Lymphoma. 2013; 54: 1159-64. doi:10.3109/10428194.2012.733880
    • (2013) Leuk Lymphoma , vol.54 , pp. 1159-1164
    • Zou, Z.J.1    Zhang, R.2    Fan, L.3    Wang, L.4    Fang, C.5    Zhang, L.N.6    Yang, S.7    Li, Y.Y.8    Li, J.Y.9    Xu, W.10
  • 25
    • 84921779149 scopus 로고    scopus 로고
    • miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation
    • Zou Z-J, Fan L, Wang L, Xu J, Zhang R, Tian T, Li J-Y, Xu W. miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation. Oncotarget. 2015; 6: 1276-85. doi: 10.18632/oncotarget.2626
    • (2015) Oncotarget , vol.6 , pp. 1276-1285
    • Zou, Z.-J.1    Fan, L.2    Wang, L.3    Xu, J.4    Zhang, R.5    Tian, T.6    Li, J.-Y.7    Xu, W.8
  • 26
    • 77957739848 scopus 로고    scopus 로고
    • Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia
    • Shehata M, Schnabl S, Demirtas D, Hilgarth M, Hubmann R, Ponath E, Badrnya S, Lehner C, Hoelbl A, Duechler M, Gaiger A, Zielinski C, Schwarzmeier JD, et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood. 2010; 116: 2513-21. doi:10.1182/blood-2009-10-248054
    • (2010) Blood , vol.116 , pp. 2513-2521
    • Shehata, M.1    Schnabl, S.2    Demirtas, D.3    Hilgarth, M.4    Hubmann, R.5    Ponath, E.6    Badrnya, S.7    Lehner, C.8    Hoelbl, A.9    Duechler, M.10    Gaiger, A.11    Zielinski, C.12    Schwarzmeier, J.D.13
  • 27
    • 77957961828 scopus 로고    scopus 로고
    • Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia
    • Martins LR, Lúcio P, Silva MC, Anderes KL, Gameiro P, Silva MG, Barata JT. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood. 2010; 116: 2724-31. doi:10.1182/blood-2010-04-277947
    • (2010) Blood , vol.116 , pp. 2724-2731
    • Martins, L.R.1    Lúcio, P.2    Silva, M.C.3    Anderes, K.L.4    Gameiro, P.5    Silva, M.G.6    Barata, J.T.7
  • 28
    • 84877739002 scopus 로고    scopus 로고
    • The phosphoinositide 3-kinase pathway in chronic lymphocytic leukemia: evidence for phosphatase and tensin homolog deletion on chromosome 10 deregulation
    • Best OG, Mulligan SP. The phosphoinositide 3-kinase pathway in chronic lymphocytic leukemia: evidence for phosphatase and tensin homolog deletion on chromosome 10 deregulation. Leuk Lymphoma. 2013; 54: 1123-4. doi:10.3109/10428194.2012.746685
    • (2013) Leuk Lymphoma , vol.54 , pp. 1123-1124
    • Best, O.G.1    Mulligan, S.P.2
  • 30
    • 85028735413 scopus 로고    scopus 로고
    • doi: 10.1007/s11010-011-0947-6
  • 31
    • 84893861633 scopus 로고    scopus 로고
    • Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor
    • Martins LR, Perera Y, Lúcio P, Silva MG, Perea SE, Barata JT. Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor. Oncotarget. 2014; 5: 258-63. doi: 10.18632/ oncotarget.1513
    • (2014) Oncotarget , vol.5 , pp. 258-263
    • Martins, L.R.1    Perera, Y.2    Lúcio, P.3    Silva, M.G.4    Perea, S.E.5    Barata, J.T.6
  • 32
    • 74249089749 scopus 로고    scopus 로고
    • Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-alpha3 binding
    • Marchenko ND, Hanel W, Li D, Becker K, Reich N, Moll UM. Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-alpha3 binding. Cell Death Differ. 2010; 17: 255-67. doi: 10.1038/ cdd.2009.173
    • (2010) Cell Death Differ , vol.17 , pp. 255-267
    • Marchenko, N.D.1    Hanel, W.2    Li, D.3    Becker, K.4    Reich, N.5    Moll, U.M.6
  • 33
    • 34249295787 scopus 로고    scopus 로고
    • Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma
    • Becker K, Marchenko ND, Maurice M, Moll UM. Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma. Cell Death Differ. 2007; 14: 1350-60. doi: 10.1038/sj.cdd.4402126
    • (2007) Cell Death Differ , vol.14 , pp. 1350-1360
    • Becker, K.1    Marchenko, N.D.2    Maurice, M.3    Moll, U.M.4
  • 34
    • 84859111172 scopus 로고    scopus 로고
    • ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage
    • Khoronenkova SV, Dianova II, Ternette N, Kessler BM, Parsons JL, Dianov GL. ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Mol Cell. 2012; 45: 801-13. doi: 10.1016/j. molcel.2012.01.021
    • (2012) Mol Cell , vol.45 , pp. 801-813
    • Khoronenkova, S.V.1    Dianova, I.I.2    Ternette, N.3    Kessler, B.M.4    Parsons, J.L.5    Dianov, G.L.6
  • 37
    • 84953455252 scopus 로고    scopus 로고
    • microRNA and Chronic Lymphocytic Leukemia
    • Giza DE, Calin GA. microRNA and Chronic Lymphocytic Leukemia. Adv Exp Med Biol. 2015; 889: 23-40. doi:10.1007/978-3-319-23730-5_2
    • (2015) Adv Exp Med Biol , vol.889 , pp. 23-40
    • Giza, D.E.1    Calin, G.A.2
  • 40
    • 85028706673 scopus 로고    scopus 로고
    • doi: 10.1007/978-1-4614-8051-8_14
  • 42
    • 84885658308 scopus 로고    scopus 로고
    • CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway
    • Prins RC, Burke RT, Tyner JW, Druker BJ, Loriaux MM, Spurgeon SE. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia. 2013; 27: 2094-6. doi: 10.1038/leu.2013.228
    • (2013) Leukemia , vol.27 , pp. 2094-2096
    • Prins, R.C.1    Burke, R.T.2    Tyner, J.W.3    Druker, B.J.4    Loriaux, M.M.5    Spurgeon, S.E.6
  • 43
    • 84862005662 scopus 로고    scopus 로고
    • Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways
    • Piazza F, Manni S, Ruzzene M, Pinna LA, Gurrieri C, Semenzato G. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia. 2012; 26: 1174-9. doi: 10.1038/leu.2011.385
    • (2012) Leukemia , vol.26 , pp. 1174-1179
    • Piazza, F.1    Manni, S.2    Ruzzene, M.3    Pinna, L.A.4    Gurrieri, C.5    Semenzato, G.6
  • 45
    • 84893861633 scopus 로고    scopus 로고
    • Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor
    • Martins LR, Perera Y, Lúcio P, Silva MG, Perea SE, Barata JT. Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor. Oncotarget. 2014; 5: 258-63. doi: 10.18632/ oncotarget.1513
    • (2014) Oncotarget , vol.5 , pp. 258-263
    • Martins, L.R.1    Perera, Y.2    Lúcio, P.3    Silva, M.G.4    Perea, S.E.5    Barata, J.T.6
  • 49
    • 84860160285 scopus 로고    scopus 로고
    • Selective inhibition of USP7
    • Menard R, Sulea T. Selective inhibition of USP7. Chem Biol. 2012; 19: 437-8. doi: 10.1016/j.chembiol.2012.04.001
    • (2012) Chem Biol , vol.19 , pp. 437-438
    • Menard, R.1    Sulea, T.2
  • 50
    • 76449094879 scopus 로고    scopus 로고
    • The therapeutic potential of deubiquitinating enzyme inhibitors
    • Colland F. The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans. 2010; 38: 137-43. doi: 10.1042/BST0380137
    • (2010) Biochem Soc Trans , vol.38 , pp. 137-143
    • Colland, F.1
  • 52
    • 84922393807 scopus 로고    scopus 로고
    • Ubiquitination in disease pathogenesis and treatment
    • Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014; 20: 1242-53. doi: 10.1038/nm.3739
    • (2014) Nat Med , vol.20 , pp. 1242-1253
    • Popovic, D.1    Vucic, D.2    Dikic, I.3
  • 53
    • 84896765296 scopus 로고    scopus 로고
    • Idelalisib-a PI3Kd inhibitor for B-cell cancers
    • Fruman DA, Cantley LC. Idelalisib-a PI3Kd inhibitor for B-cell cancers. N Engl J Med. 2014; 370: 1061-2. doi:10.1056/NEJMe1400055
    • (2014) N Engl J Med , vol.370 , pp. 1061-1062
    • Fruman, D.A.1    Cantley, L.C.2
  • 55
    • 84860217431 scopus 로고    scopus 로고
    • The functions and regulation of the PTEN tumour suppressor
    • Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012; 13: 283-96. doi: 10.1038/nrm3330
    • (2012) Nat Rev Mol Cell Biol , vol.13 , pp. 283-296
    • Song, M.S.1    Salmena, L.2    Pandolfi, P.P.3
  • 56
    • 78651482046 scopus 로고    scopus 로고
    • Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphataseindependent manner
    • Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, Pandolfi PP. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphataseindependent manner. Cell. 2011; 144: 187-99. doi:10.1016/j.cell.2010.12.020
    • (2011) Cell , vol.144 , pp. 187-199
    • Song, M.S.1    Carracedo, A.2    Salmena, L.3    Song, S.J.4    Egia, A.5    Malumbres, M.6    Pandolfi, P.P.7
  • 57
    • 33845999615 scopus 로고    scopus 로고
    • Essential role for nuclear PTEN in maintaining chromosomal integrity
    • Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007; 128: 157-70. doi:10.1016/j.cell.2006.11.042
    • (2007) Cell , vol.128 , pp. 157-170
    • Shen, W.H.1    Balajee, A.S.2    Wang, J.3    Wu, H.4    Eng, C.5    Pandolfi, P.P.6    Yin, Y.7
  • 60
  • 63
    • 68849118992 scopus 로고    scopus 로고
    • The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation
    • Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M, Tuschl T, Ponzetto C. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest. 2009; 119: 2366-78. doi:10.1172/JCI38075
    • (2009) J Clin Invest , vol.119 , pp. 2366-2378
    • Taulli, R.1    Bersani, F.2    Foglizzo, V.3    Linari, A.4    Vigna, E.5    Ladanyi, M.6    Tuschl, T.7    Ponzetto, C.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.